Login to Your Account

Pharma: Clinic Roundup

Friday, May 25, 2012

• Boehringer Ingelheim Pharmaceuticals Inc., of Ingelheim, Germany, and Eli Lilly and Co., of Indianapolis, reported Phase III results for Tradjenta (linagliptin) 5 mg once-daily, which showed significant hemoglobin A1c reduction of 0.88 percent compared with 0.24 percent in the placebo group at 24 weeks.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription